Skip to main navigation
  • Investors

    Investors

    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZYN002 CBD Gel
    • CONNECT-FX Trial
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q
    • DEE
    • Epilepsy

Enhanced SEC Filings

SEC Filing Keyword Search

Filing date Form Description View
Oct 9, 2014 D
0001621443-14-000001.rtf
0001621443-14-000001.xls
0001621443-14-000001.pdf

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Current page 45

Investor Relations

  • Investor Relations
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts

Investor Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • Privacy Policy
  • Terms of Use
  • Contact Us

© 2023 Zynerba Pharmaceuticals, Inc. All rights reserved.

zynerba inverted logo

80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
484.581.7505